Association of variations in monoamine oxidases A and B with Parkinson's disease subgroups

被引:20
|
作者
Parsian, A
Racette, B
Zhang, ZH
Rundle, M
Perlmutter, JS
机构
[1] Univ Louisville, Hlth Sci Ctr, Dept Mol & Cellular Biol, Louisville, KY 40292 USA
[2] Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA
[3] Washington Univ, Sch Med, Dept Radiol, St Louis, MO 63110 USA
[4] Washington Univ, Sch Med, Dept Neurobiol, St Louis, MO 63110 USA
关键词
Parkinson; monoamine oxidases A and B; genetics; polymorphism;
D O I
10.1016/j.ygeno.2003.09.002
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Idiopathic Parkinson's disease (PD) is an age dependent, neurodegenerative disorder and is predominantly a sporadic disease. A minority of patients has a positive family history for PD and the majority of those families exhibit a complex mode of inheritance. The monoamine oxidases A and B (MAO-A and -B) genes, which are involved in serotonin and dopamine metabolism, are possible candidate genes for susceptibility to PD. Previous association studies of MAO-A and -B in PD have been inconclusive. To determine the role of MAO-A and -B in the development of PD, we screened a sample of 96 patients with familial PD, 164 with sporadic PD, and 180 matched normal controls with dinucleotide repeat markers in these genes. MAO-A and -B gene polymorphisms were strongly associated with total PD (p<0.00001), familial PD (p<0.00001), and sporadic PD (p<0.00001). There were no significant differences between familial or sporadic PD with age of onset younger than 50 years compared to those with age of onset older than 51 years for both MAO-A and -B genes. There was no linkage disequilibrium between these genes in male PD and control groups. The frequency of common haplotypes from MAO-A and -B was different in PD and control group (p = 0.02). Our data indicate that MAO-A and -B may play a role in susceptibility to PD in our sample. (C) 2003 Elsevier Inc. All rights reserved.
引用
收藏
页码:454 / 460
页数:7
相关论文
共 50 条
  • [31] MOLECULAR-PROPERTIES OF MONOAMINE OXIDASES A AND B
    KWAN, SW
    BERGERON, JM
    ABELL, CW
    PSYCHOPHARMACOLOGY, 1992, 106 : S1 - S5
  • [32] Activatable organic upconversion nanoprobe for bioimaging of monoamine oxidase B in Parkinson's disease
    Zhang, Yuanyuan
    Wang, Jing
    Yi, Wanxiang
    Tiemuer, Aliya
    Yu, Hui
    Liu, Yi
    Su, Dan
    SENSORS AND ACTUATORS B-CHEMICAL, 2023, 389
  • [33] Functional mechanism of neuroprotection by inhibitors of type B monoamine oxidase in Parkinson's disease
    Naoi, Makoto
    Maruyama, Wakako
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2009, 9 (08) : 1233 - 1250
  • [34] Preclinical evidence for neuroprotection with monoamine oxidase-B inhibitors in Parkinson's disease
    Jenner, P
    NEUROLOGY, 2004, 63 (07) : S13 - S22
  • [35] Altered Platelet Monoamine Oxidase-B Activity in Idiopathic Parkinson’s Disease
    Maroof Husain
    Rakesh Shukla
    Madhu Dikshit
    Pradeep K. Maheshwari
    Devika Nag
    Rikhab C. Srimal
    Prahlad K. Seth
    Vinay K. Khanna
    Neurochemical Research, 2009, 34 : 1427 - 1432
  • [36] ACTIVITY OF A-MONOAMINE AND B-MONOAMINE OXIDASES IN HYPERBARIC OXYGENATION
    GOROSHINSKAYA, IA
    VOPROSY MEDITSINSKOI KHIMII, 1979, 25 (03): : 328 - 333
  • [37] Monitoring of Monoamine Oxidases as Biomarkers of Disease and Disorder
    Kim, Dokyoung
    Beck, Sungjun
    Jung, Junyang
    BULLETIN OF THE KOREAN CHEMICAL SOCIETY, 2018, 39 (03): : 277 - 278
  • [38] The increasing role of monoamine oxidase type B inhibitors in Parkinson's disease therapy
    Elmer, Lawrence W.
    Bertoni, John M.
    EXPERT OPINION ON PHARMACOTHERAPY, 2008, 9 (16) : 2759 - 2772
  • [39] Garcinol, an effective monoamine oxidase-B inhibitor for the treatment of Parkinson's disease
    Mazumder, Muhammed Khairujjaman
    Paul, Rajib
    Phukan, Banashree Chetia
    Dutta, Ankumoni
    Chakrabarty, Jayasree
    Bhattacharya, Pallab
    Borah, Anupom
    MEDICAL HYPOTHESES, 2018, 117 : 54 - 58
  • [40] The Role of Monoamine Oxidase B Inhibitors in the Treatment of Parkinson's Disease-An Update
    Chew, Zhi Xin
    Lim, Chooi Ling
    Ng, Khuen Yen
    Chye, Soi Moi
    Ling, Anna Pick Kiong
    Koh, Rhun Yian
    CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, 2023, 22 (03) : 329 - 352